Substrate
Topic

breast-reconstruction

1 stories related to this topic, newest first.

Elutia Reports $3.1 Million in Q1 2026 Net Sales, Up 6% Year-over-YearBenzinga
finance14 days agoDeveloping

Elutia Reports $3.1 Million in Q1 2026 Net Sales, Up 6% Year-over-Year

Elutia released first-quarter results on May 14, 2026, showing improved gross margin and progress on its automated manufacturing platform. The company anticipates FDA clearance for its NXT41 product in Q4 2026. CEO Randy Mills highlighted the $1.5 billion U.S. breast reconstructi…

Benzinga
1 source